NCT07039474

The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 120 (estimated)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy

Detailed description

It is urgent to select patients who will benefit from immunotherapy, so as to help the clinicians adjust the regimens and avoid unnecessary side effect. 18F-G1 is a new radioactive tracer targeting granzyme B, holding great promise in assessing early response to immunotherapy. This study will explore the safety of 18F-G1 PET/CT in patients with solid tumors and hematological tumors receiving immunotherapy, analyze its imaging features, and assess its efficacy in predicting early immunotherapy response and prognosis, so as to aid the clinicians in precise patient stratification and regimen adjustment.

Conditions

• Solid Tumors and Hematological Tumors

Interventions

Type	Name	Description
DRUG	18F-G1	18F-G1 is injected intravenously with a dose of 0.06-0.08mCi/kg

Timeline

• Start date: 2025-07-15
• Primary completion: 2026-12-31
• Completion: 2027-06-01
• First posted: 2025-06-26
• Last updated: 2025-06-26